ArticlePostepy dermatologii i alergologii2023
Efficacy of apremilast for psoriasis: a meta-analysis of randomized controlled studies.
Article in Postepy dermatologii i alergologii, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- From Convenience to Clinical Efficacy: Selective TYK2 Inhibition in Psoriasis and the Evolving Role of Next-Generation Oral Targeted Therapies.Pharmaceutics · 2026Review
- Application of Trichoscopy and Novel Non-Invasive Imaging Techniques in the Diagnosis and Management of Patients with Scalp Psoriasis.Psoriasis (Auckland, N.Z.) · 2026Review
- The efficacy of apremilast in pemphigus: a systematic review of case reports.Dermatology reports · 2025Article
- Bibliometric analysis and description of research trends on T cells in psoriasis over the past two decades (2003-2022).Heliyon · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The efficacy of apremilast for psoriasis remains controversial. Aim: We have conducted a systematic review and meta-analysis to explore the influence of apremilast on treatment efficacy for psoriasis. Material and methods: We have searched PubMed, Embase, Web of science, EBSCO, and Cochrane library databases for randomized controlled trials (RCTs) published until February 2022 and assessing the efficacy and safety of apremilast for psoriasis. This meta-analysis was performed using the random-effects model. Results: Seven RCTs were included in the meta-analysis. Overall, compared with placebo for psoriasis, apremilast was associated with improved PASI-75 (LOCF) (OR = 6.59; 95% CI: 4.55 to 9.53; Conclusions: Apremilast is effective and safe to treat psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.